Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05467176 · ClinicalTrials.gov registry record
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
A clinical trial of Prostate Cancer, sponsored by Sumitomo Pharma America.
- Active
- Registry status
- 999
- Enrollment target
- 20
- Study locations
NCT05467176 is a study of Prostate Cancer that is active but no longer recruiting, run by Sumitomo Pharma America. The registered enrollment target is 999 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT05467176, a study of Prostate Cancer, is active but no longer recruiting, sponsored by Sumitomo Pharma America.
- ACTIVE NOT RECRUITING
- Registry status
- 999 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.
Conditions Studied
Interventions
- DRUG Relugolix
Study Locations (20)
California
- City of Hope - Duarte
- Urology Associates of Central California - Fresno
- UCSD - La Jolla
- USC Norris Cancer Center - Los Angeles
- Tower Urology - Los Angeles
- VA Greater Los Angeles Medical Center - Los Angeles
- Tri Valley Urology - Murrieta
- Genesis Research LLC - San Diego
- Golden State Urology - Stockton
Colorado
- Rocky Mountain Regional VA Medical Center - Aurora
- The Urology Center of Colorado - Denver
- Banner MD Anderson Cancer Center - Greeley
- Colorado Urology - Lakewood
- Urology Associates - Lone Tree
Alabama
- Urology Centers of Alabama - Homewood
- Urology Associates of Mobile - Mobile
Arizona
- Dignity Health - Phoenix
- Arizona Urology Specialists, PLLC - Tucson
Arkansas
- Arkansas Urology Research Center - Little Rock
Connecticut
- The Stamford Hospital - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 999 participants |
| Start Date | 2022-10-04 |
| Est. Completion | 2028-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05467176
The ClinicalTrials.gov registry entry for NCT05467176 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 999 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Relugolix is the first listed.
NCT05467176 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT05467176 about?
NCT05467176 is a clinical study titled "A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX". This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment ...
What is the current status of trial NCT05467176?
This trial is currently active not recruiting. The enrollment target is 999 participants. The study started on 2022-10-04. Estimated completion is 2028-05-31.
What conditions does trial NCT05467176 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05467176?
The interventions under investigation include: Relugolix (DRUG).
Who is sponsoring clinical trial NCT05467176?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05467176 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.